Abstract
In reply The interpretation of our findings offered by Wendel is undoubtedly shared by others. In our article, 1 we acknowledge that we did not study the reasons why, during the first 3 years after the Food and Drug Administration granted approval, zidovudine was used at a lower rate by patients with acquired immunodeficiency syndrome (AIDS) who received most of their ambulatory care from generalist physicians and clinics compared with those who received most of their ambulatory care from specialists or AIDS specialty clinics. Wendel suggests that the rapid adoption of new technologies is not always sound, and he uses prostatic serum antigen screening for prostatic carcinoma as an example. We agree that generalists should use caution when applying an expensive screening test to a large segment of the population. With regard to our findings, Wendel hypothesized that generalists were probably being cautious and needed more substantial proof of the
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.